Seonda Laboratories

Seonda Laboratories is a South Korean biotechnology company focused on the development of novel therapeutics targeting cancer stem cells (CSCs). The company's primary research centers on the Signal Transducer and Activator of Transcription 3 (STAT3) pathway, which plays a critical role in tumor growth, metastasis, and drug resistance. Its lead candidate, SD-101, is a small molecule STAT3 inhibitor designed to treat various solid tumors, including gastric and colorectal cancers. Seonda was acquired by the HLB Group, a prominent South Korean conglomerate, to bolster its oncology pipeline. The company leverages its proprietary platform to identify and inhibit key drivers of cancer recurrence.